血脂管理新理念助推临床血脂检验的发展

New concept on blood lipid management promotes the development of clinical blood lipid test

血脂异常是心脑血管疾病重要危险因素之一。大量证据表明，有效控制血脂异常降低心脑血管疾病的发生率和死亡率。近年来，血脂领域的相关研究颇为活跃，欧美和我国相继对血脂异常管理指南进行了更新。新指南虽然在是否应坚持LDL－C达到目标值，血脂检测是否需要空腹等方面有一些分歧，但无一不更加强调了不同危险分层人群血脂水平控制的重要性，强调降脂治疗应以患者为中心，提高患者的依从性。目前我国的血脂检验结果报告方式大多不能适应《血脂管理指南》中不同危险程度患者需要不同治疗目标的要求，合理的血脂指标的医学决定水平如何更好的体现在临床检验报告单中，这也是未来检验医师需要努力的方向之一。

Dyslipidemia is one of the important risk factors for cardiovascular and cerebrovascular diseases. Extensive evidence has proven that effective control of dyslipidemia can reduce the incidence and mortality of cardiovascular and cerebrovascular diseases.In recent years, related research in the field of blood lipids has been quite active.The guidelines for the management of dyslipidemia in Europe, the United States, and China have been successively updated.Although there are some disagreements on whether the LDL-C should reach the target value and whether blood lipid testing needs fasting, all of these new guidelines emphasize the importance of controlling blood lipid levels in different risk stratification groups, also emphasize that lipid-lowering therapy should be patient-centered to improve patient compliance. At present, most of the laboratory report of blood lipid test Results in China cannot meet the requirements of different therapeutic targets for patients with different risk groups in the ＂Guidelines for the management of blood lipids＂ . How to make the reasonable blood lipid reference range better reflected in the clinical test report form, is also one of the directions that future laboratory physicians need to work hard on.